ARCH, biotech's star slugger, snags another $3B for 13th fund
Bob Nelsen will tell you that ARCH Venture Partners is always chasing home runs. The early-stage VC firm has backed some of the most recognizable names in drug development, like Alnylam, bluebird bio...
View ArticleCSL Seqirus inks fifth contract with BARDA, making the partnership now worth...
CSL Seqirus has secured a fresh $121.4 million contract with the US Biomedical Advanced Research and Development Authority to manufacture and supply its adjuvanted vaccine against avian flu, bringing...
View ArticleClik here to view.
Instacart partners with 9amHealth to combine weight loss drugs with healthy...
The GLP-1 prescription startup 9amHealth is partnering with grocery delivery service Instacart to incorporate stipends for healthy foods into its treatment plans for diabetes, weight loss and heart...
View ArticleRepair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M
Plus, news about Enanta, Inventiva, Eradivir, Novo Nordisk, Evotec, Lundbeck, Iambic Therapeutics and Wave Life Sciences: Genevant Sciences, Repair Biotechnologies team up: The biotechs will work on a...
View ArticleSIGA is 'deeply angered' by former exec's 'inaccurate' comments about mpox...
SIGA Technologies said former chief medical officer Jay Varma’s comments about the company’s experimental mpox drug are “inaccurate and misleading.” The infectious disease drugmaker had already fired...
View ArticleAGC Biologics to lay off 95 workers; Vertex taps Lonza to manufacture Casgevy
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. AGC Biologics said it is laying off a total of 95 staffers, which...
View ArticleUpdated: FDA adcomm votes to limit Opdivo, Keytruda use in stomach,...
The FDA’s Oncologic Drugs Advisory Committee on Thursday voted 10-2 with one abstention that Merck’s Keytruda and Bristol Myers Squibb’s Opdivo are not beneficial as a first-line treatment for stomach...
View ArticleClik here to view.
Genentech's blood cancer drug Gazyva moves toward more indications in immunology
Genentech plans to expand the label for its CD20-targeting antibody Gazyva following positive late-stage data in an autoimmune disease that impacts the kidneys. In the Phase 3 REGENCY study, a higher...
View ArticleInsilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter...
One of the original AI-driven drug discovery and development biotechs has let its plans to list on the Hong Kong stock exchange lapse for the second time in as many years. Insilico Medicine, a...
View ArticleClik here to view.
AstraZeneca's lung cancer blockbuster Tagrisso wins label expansion in...
AstraZeneca’s blockbuster lung cancer treatment Tagrisso scored a new FDA approval on Thursday in certain EGFR-mutated early-stage patients whose non-small cell lung cancer has not spread, but can’t be...
View ArticleClik here to view.
FDA lifts hold on Biomea’s diabetes trials
The FDA lifted a clinical hold on two trials testing Biomea Fusion’s diabetes treatment. The news, announced Thursday, sent the company’s shares $BMEA up by about 4% to $9.11, inching closer to its...
View ArticleClik here to view.
FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for...
The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions. The approval gives Bristol Myers a significant foothold in the...
View ArticleClik here to view.
Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race
↑ CEO Laura Shawver Total raised $340 million Headquarters San Diego, CA Turning a patient’s own cells into powerful disease combatants — without the complexity of removing them from the body to do so...
View ArticleClik here to view.
Endpoints 11 winner Mirador Therapeutics: Applying precision medicine to...
↑ CEO Mark McKenna Total raised $400 million Headquarters San Diego, CA 2024 is on track to be a record-breaking year for venture capital funding of immunology-focused biotech startups. And Mirador...
View ArticleClik here to view.
Endpoints 11 winner Formation Bio: A Silicon Valley-fueled unicorn aiming to...
↑ CEO Benjamine Liu Total raised More than $600 million Headquarters New York, NY During his doctorate work at the University of Oxford, Benjamine Liu came across what he thought were some promising...
View ArticleClik here to view.
Endpoints 11 winner Xaira Therapeutics: Biotech’s largest AI bet with A-list...
↑ CEO Marc Tessier-Lavigne Total raised More than $1 billion in committed capital Headquarters South San Francisco, CA David Baker’s Seattle laboratory has become the place for the biopharma industry...
View ArticleClik here to view.
Endpoints 11 winner Metsera: Clive Meanwell wagers on obesity after Medicines...
↑ CEO Clive Meanwell Total raised $290 million Headquarters New York, NY Shortly after Clive Meanwell sold The Medicines Company to Novartis for nearly $10 billion in 2020, he started a life sciences...
View ArticleClik here to view.
Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology...
↑ CEO Michael Ehlers Total raised $90 million Headquarters Boston, MA Ascidian Therapeutics has a secret list of nearly 400 diseases that its gene-altering technology might help cure. But you’ll only...
View ArticleClik here to view.
Endpoints 11 winner Cardurion Pharmaceuticals: A shot at one of heart...
↑ CEO Peter Lawrence Total raised More than $500 million Headquarters Burlington, MA ‘Undruggable’ targets aren’t just in oncology. Cardurion Pharmaceuticals is hoping to become the first to...
View ArticleClik here to view.
Endpoints 11 winner Iambic Therapeutics: Entering the ‘show-me’ era for AI
↑ CEO Tom Miller Total raised $220 million Headquarters San Diego, CA As two biotech rookies leaving long academic careers to co-found Iambic in 2019, CEO Tom Miller and CTO Fred Manby were...
View Article